Investor Relations

Hauptversammlung

General Meeting

Contact: Dr. Ulrich Wandel
ulrich.wandel@shop-apotheke.com

Annual General Meeting 2019

In the following, please find information for the annual general meeting of SHOP APOTHEKE EUROPE N.V. on April 30, 2019. Please find the meeting documents below.

The number of outstanding shares and the number of votes as per March 19, 2019 amount to 12,074,926 each.

As at the Record Date (i.e. 2 April 2019), the company's issued share capital amounted to EUR 241,498.52, consisting of 12,074,926 shares in bearer form having a nominal value of EUR 0.02 each. The number of shares on which voting rights can be exercised as at the day on which the annual general meeting is convened, is 12,074,926.

Annual General Meetings Archive

Annual General Meeting 2018

In the following, please find information for the annual general meeting of SHOP APOTHEKE EUROPE N.V. on April 26, 2018. Please find the meeting documents below.

The number of outstanding shares and the number of votes as per March 13, 2018 amount to:

Number of outstanding shares : 12,020,456
Number of voting rights during AGM : 12,020,456

 

Extraordinary General Meeting 2017

In the following, please find information for the extraordinary general meeting of SHOP APOTHEKE EUROPE N.V. on November 06, 2017. Please find the meeting documents below.

The number of outstanding shares and the number of votes as per September 25, 2017 amount to:

Number of outstanding shares: 9,069,878
Number of voting rights during AGM: 9,069,878

 

Annual General Meeting 2017

In the following, please find information for the annual general meeting of SHOP APOTHEKE EUROPE N.V. on May 16, 2017. Please find the meeting documents below.

The number of outstanding shares and the number of votes as per April 4, 2017 amount to:

Number of outstanding shares: 9,069,878
Number of voting rights during AGM: 9,069,878

Events

14. August 2019

Halbjahresfinanzbericht

14 August 2019

Half-year Report

14. November 2019

Zwischenmitteilung Q3

14 November 2019

Interim Statement Q3